REG - Avacta Group PLC - Posting of Annual Report and Notice of AGM

AvactaAnnouncement

02/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230602:nRSB4145Ba&default-theme=true

RNS Number : 4145B  Avacta Group PLC  02 June 2023

 

02 June 2023

 

Avacta Group plc

 

("Avacta" or the "Company" and, together with its subsidiary undertakings, the
"Group")

 

Posting of Annual Report and Notice of AGM

 

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative,
targeted oncology drugs and powerful diagnostics, today announces that its
Annual Report and Accounts for the year ended 31 December 2022 and the Notice
of the 2023 Annual General Meeting ("AGM") are now available on the Company's
website at www.avacta.com/investors/documents
(http://www.avacta.com/investors/documents) .

Copies of the Annual Report and Accounts and the Notice of the AGM have been
posted to registered shareholders who have elected to receive them in paper
form.

The Annual General Meeting will be held on Wednesday, 28 June 2023 at 10.30
a.m. BST at The Royal Society of Medicine, 1 Wimpole Street, Westminster,
London W1G 0AE (the "Venue").

The Venue has a capacity of approximately 140 people. Registered shareholders
have a right to attend the AGM.  In addition, the current expectation is that
the chair of the AGM will, at their discretion, permit beneficial shareholders
to attend in person. Shareholders (registered or beneficial) who propose to
attend the AGM in person are requested to pre-register their interest and, to
assist the Company in its preparation for the AGM, prove their shareholding by
emailing FTI Consulting at avacta.ls@fticonsulting.com
(mailto:avacta.ls@fticonsulting.com) by 10:30 a.m. BST on 27 June 2023. Any
failure to pre-register will not, of itself, preclude a registered shareholder
from attending the AGM in person (or by proxy).

Only registered shareholders who attend in person or by proxy will be able to
vote on the day. Details of how to submit a proxy vote are contained in the
Notice of the AGM.

The Company will provide a business update following the AGM, which will be
streamed live on the Investor Meet Company platform. Investors who already
follow Avacta on Investor Meet Company will automatically be invited to join
the live stream. Investors who do not have an Investor Meet Company account
can sign up for free via the following link
https://www.investormeetcompany.com/avacta-group-plc/register-investor
(https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.investormeetcompany.com%2Favacta-group-plc%2Fregister-investor&data=05%7C01%7Cmichael.vinegrad%40avacta.com%7C0210a0a144924162243b08db5ae1f88e%7C64d2165ff9e04869bc73bfe4fc4fa9ab%7C0%7C0%7C638203698853727284%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=9I4VgPnOAqL2MipHikvNpSzN6NxbB72xb2bBFEETykY%3D&reserved=0)
and then click "Add to meet" Avacta Group in order to receive an invitation
for the live stream. Those attending in person will be able to meet with a
range of Avacta staff, view recently presented data posters and hear
additional technical presentations.

Early pre-registration to attend the AGM in person is recommended as the
Venue's capacity is limited (as referred to above) and, for non-registered
shareholders, registrations will be dealt with on a first come, first served
basis.

All presentation materials will be made available on the website at the end of
the day and no new material information will be provided.

 

-Ends-

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                                                Tel: +44 (0) 1904 21 7070

 Alastair Smith, Chief Executive Officer                                         www.avacta.com (http://www.avacta.com)

 Tony Gardiner, Chief Financial Officer

 Michael Vinegrad, Group Communications Director

 Stifel Nicolaus Europe Limited (Nomad and Broker)                               Tel: +44 (0) 207 710 7600

 Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Dhiren Suares   www.stifel.com (http://www.stifel.com/)
 / William Palmer-Brown

 FTI Consulting (Financial Media and IR)                                         Tel: +44(0) 203 727 1000

 Simon Conway / Alex Shaw                                                        Avacta.LS@fticonsulting.com (mailto:Avacta.LS@fticonsulting.com)

 Zyme Communications (Trade and Regional Media)                                  Tel: +44 (0)7891 477 378

 Lily Jeffery                                                                    lily.jeffery@zymecommunications.com

                                                                               (mailto:katie.odgaard@zymecommunications.com)

 

About Avacta Group plc - www.avacta.com (http://www.avacta.com)

 

Avacta Group plc is a life sciences company working to improve people's health
and well-being through innovative oncology drugs and powerful diagnostics.
Operating through two divisions, Diagnostics and Therapeutics, the Group's
mission is to provide professionals and consumers with solutions that improve
healthcare, fitness and well-being.

 

Avacta's Therapeutics Division, a clinical stage oncology drug innovator, is
building a wholly owned pipeline of novel Affimer(®) immunotherapies and
pre|CISION™ tumour targeted chemotherapies. This approach is designed to
address the lack of a durable response to current cancer immunotherapies
experienced by most patients and reduce the severe systemic toxicities caused
by chemotherapies. There are five programmes in the pipeline as well as
several global research collaborations and licensing partnerships. Avacta's
lead programme, AVA6000, is a pre|CISION™ tumour-targeted form of the
established chemotherapy doxorubicin. AVA6000 is in Phase I clinical trials in
patients with locally advanced or metastatic selected solid tumours.

 

The Affimer(®) platform is an alternative to antibodies that has been
designed to address many of the drawbacks of antibodies which, despite their
shortcomings, currently dominate the immuno-diagnostics and
immuno-therapeutics markets.

 

The pre|CISION™ tumour targeting platform can be used to modify a
chemotherapy in order to selectively release the active drug in tumour tissue
thereby reducing the systemic exposure that causes damage to healthy tissues.
pre|CISION™ modified chemotherapies are designed to reduce the side effects
and improve the overall safety and therapeutic potential of these powerful
anti-cancer treatments.

 

Avacta's Diagnostics Division develops and supplies a broad range of in-vitro
diagnostic (IVD) solutions. The Division is growing rapidly through an M&A
strategy to deliver a global scale IVD business providing market leading
solutions for healthcare professionals and consumers to inform treatment and
monitor health and well-being. In October 2022, Avacta acquired Launch
Diagnostics which serves the hospital pathology laboratory market in the UK
and Europe. In May 2023, Avacta acquired Coris Bioconcept a Belgium based
lateral flow test developer and manufacturer adding a broad range of marketed
professional-use rapid tests into the Diagnostics Division. Avacta
Diagnostic's research and development centre in Wetherby, UK uses its
proprietary Affimer(®) platform to differentiate immunodiagnostic products to
provide marketing leading performance.

 

To register for news alerts by email go to
www.avacta.com/investor-news-email-alerts
(http://www.avacta.com/investor-news-email-alerts)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAUPUACQUPWGQG